Unknown

Dataset Information

0

Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation.


ABSTRACT: This report describes the results of 2 international randomized trials (total of 508 kidney transplant recipients). The primary objective was to assess the noninferiority of rabbit anti-thymocyte globulin (rATG, Thymoglobulin® ) versus interleukin-2 receptor antagonists (IL2RAs) for the quadruple endpoint (treatment failure defined as biopsy-proven acute rejection, graft loss, death, or loss to follow-up) to serve as the pivotal data for United States (US) regulatory approval of rATG. The pooled analysis provided an incidence of treatment failure of 25.1% in the rATG and 36.0% in the IL2RA treatment groups, an absolute difference of -10.9% (95% confidence interval [CI] -18.8% to -2.9%) supporting noninferiority (noninferiority margin was 10%) and superiority of rATG to IL2RA. In a meta-analysis of 7 trials comparing rATG with an IL2RA, the difference in the proportion of patients with BPAR at 12 months was -4.8% (95% CI -8.6% to -0.9%) in favor of rATG. In conclusion, a rigorous reanalysis of patient-level data from 2 prior randomized, controlled trials comparing rATG versus IL-2R monoclonal antibodies provided support for regulatory approval for rATG for induction therapy in renal transplant, making it the first T cell-depleting therapy approved for the prophylaxis of acute rejection in patients receiving a kidney transplant in the United States.

SUBMITTER: Alloway RR 

PROVIDER: S-EPMC6767488 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation.

Alloway Rita R RR   Woodle E Steve ES   Abramowicz Daniel D   Segev Dorry L DL   Castan Remi R   Ilsley Jillian N JN   Jeschke Kari K   Somerville Kenneth Troy KT   Brennan Daniel C DC  

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20190403 8


This report describes the results of 2 international randomized trials (total of 508 kidney transplant recipients). The primary objective was to assess the noninferiority of rabbit anti-thymocyte globulin (rATG, Thymoglobulin<sup>®</sup> ) versus interleukin-2 receptor antagonists (IL2RAs) for the quadruple endpoint (treatment failure defined as biopsy-proven acute rejection, graft loss, death, or loss to follow-up) to serve as the pivotal data for United States (US) regulatory approval of rATG.  ...[more]

Similar Datasets

| S-EPMC6248318 | biostudies-literature
| S-EPMC10479633 | biostudies-literature
| S-EPMC3166096 | biostudies-literature
| S-EPMC8573716 | biostudies-literature
| S-EPMC3681879 | biostudies-literature
| S-EPMC2731691 | biostudies-literature
| S-EPMC5985128 | biostudies-literature
2008-11-10 | GSE10040 | GEO
| S-EPMC3777606 | biostudies-literature
| S-EPMC6260834 | biostudies-literature